These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Predictive value of cross-matching for transfusion of platelet concentrates to alloimmunized recipients. Filip DJ; Duquesnoy RJ; Aster RH Am J Hematol; 1976; 1(4):471-9. PubMed ID: 1008059 [TBL] [Abstract][Full Text] [Related]
7. Transfusion strategy: use of HLA-matched platelet transfusions for alloimmunized patients. Menitove JE; Duquesnoy RJ Am J Med Technol; 1981 Feb; 47(2):114-20. PubMed ID: 7223758 [TBL] [Abstract][Full Text] [Related]
8. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Petz LD; Garratty G; Calhoun L; Clark BD; Terasaki PI; Gresens C; Gornbein JA; Landaw EM; Smith R; Cecka JM Transfusion; 2000 Dec; 40(12):1446-56. PubMed ID: 11134563 [TBL] [Abstract][Full Text] [Related]
10. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. McFarland JG; Anderson AJ; Slichter SJ Br J Haematol; 1989 Nov; 73(3):380-6. PubMed ID: 2605125 [TBL] [Abstract][Full Text] [Related]
11. HLA-matched platelet transfusions are effective only in refractory patients with positive HLA antibody screening. Kreuger AL; Mäkelburg ABU; Somers JAE; Tomson B; van de Watering LMG; van der Bom JG; van Kraaij MGJ; Weller CM Transfusion; 2019 Nov; 59(11):3303-3307. PubMed ID: 31602653 [TBL] [Abstract][Full Text] [Related]
13. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets. Levy L; Woodfield DG N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558 [TBL] [Abstract][Full Text] [Related]
14. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Brand A; van Leeuwen A; Eernisse JG; van Rood JJ Blood; 1978 May; 51(5):781-8. PubMed ID: 346088 [TBL] [Abstract][Full Text] [Related]
16. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR]. Gao SQ; Xu YP; Luo CR; Li DC; Pen L; Liu T; Zou QC Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929 [TBL] [Abstract][Full Text] [Related]
17. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366 [TBL] [Abstract][Full Text] [Related]
18. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy. Brubaker DB; Romine M Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931 [TBL] [Abstract][Full Text] [Related]
19. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets]. Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437 [TBL] [Abstract][Full Text] [Related]
20. Alloimmunization to public HLA antigens in multi-transfused platelet recipients. MacPherson BR; Hammond PB; Maniscalco CA Ann Clin Lab Sci; 1986; 16(1):38-44. PubMed ID: 3947028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]